Isomorphic Labs完成50亿美元C轮融资
Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO
Isomorphic Labs宣布完成50亿美元C轮融资,资金将用于借助AI设计和开发新药。本轮融资由Greenoaks和红杉资本共同领投,Andreessen Horowitz参与,Alphabet也进行了投资。公司称将推进基础生物学模型、疾病理解及首批治疗项目,目标是推动其进入临床试验;Dealroom数据显示,2026年药物发现初创公司融资总额达232亿美元。
这轮融资显示投资者正加大对AI药物研发公司的资金投入,也提供了观察该赛道资本流向的具体案例。
Google DeepMind's Demis Hassabis speaks at the 2026 Google I/O technology developer conference in Mountain View, California, May 19, 2026.
Karl Mondon | Afp | Getty Images
Isomorphic Labs, an artificial intelligence drug discovery startup founded by former Google DeepMind chief Demis Hassabis, has raised a $5 billion Series C, the company said on Tuesday.
Isomorphic's round comes three-and-a-half months after Hassabis stepped back as CEO of DeepMind, Google's AI lab, which he co-founded before the Big Tech giant acquired it in 2014.
The round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz, with investment from Alphabet, Google's parent. The fresh funds will help fund the design and development of new medicines using AI.
Drug discovery startups have seen record funding poured into them by investors in 2026 as companies look to capitalize on advances in AI. OpenAI and Anthropic have also been investing in tools to develop new medicines using the technology.
Hassabis has been CEO of Isomorphic Labs since the startup spun out of DeepMind in 2021.
"When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," said Hassabis.
"This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients," he added.
Isomorphic is building a proprietary drug design engine and therapeutic candidate pipeline designed with AI, which it says will help it deliver the next generation of medicines.
Anthropic announced it was launching an AI drug discovery program in June and OpenAI partnered with Novo Nordisk in April.
Drug discovery startups have raised $23.2 billion in 2026, according to deal-counting platform Dealroom, a record figure.
Isomorphic last raised in May, with a $2.1 billion Series B.
来源:CNBC · cnbc.com